BRAIN Biotech AG (ETR:BNN)

Market Cap	63.14M +41.7%
Revenue (ttm)	48.31M -9.7%
Net Income	-11.02M
EPS	-0.51
Shares Out	21.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262
Open	2.900
Previous Close	2.710
Day's Range	2.800 - 2.900
52-Week Range	1.805 - 3.890
Beta	0.63
Analysts	Strong Buy
Price Target	5.50 (+90.31%)
Earnings Date	May 28, 2026

About BRAIN Biotech AG

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bio...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1993
• Employees: 280
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BNN

Financial Performance

In fiscal year 2025, BRAIN Biotech AG's revenue was 50.22 million, a decrease of -9.52% compared to the previous year's 55.50 million. Losses were -11.74 million, 5.53% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for BNN stock is "Strong Buy." The 12-month stock price target is €5.50, which is an increase of 90.31% from the latest price.

Price Target

€5.50

(90.31% upside)

Analyst Consensus: Strong Buy